Cardioprotective effects of ω -3 PUFAs in chronic kidney disease

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Lee, Su Mi ^a   An, Won Suk ^b  

^a Seoul National University Hospital   (South Korea)

^b Dong A University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; FISH OIL; OLEIC ACID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; TRIACYLGLYCEROL; VITAMIN D; CARDIOTONIC AGENT;

ANTIARRHYTHMIC ACTIVITY; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONCENTRATION (PARAMETERS); DIET SUPPLEMENTATION; DRUG EFFECT; ERYTHROCYTE MEMBRANE; HEART PROTECTION; HUMAN; INFLAMMATION; LIPID METABOLISM; MOLECULAR MECHANICS; MORTALITY; OXIDATIVE STRESS; REVIEW; RISK REDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; CARDIOVASCULAR DISEASES; DRUG EFFECTS; METABOLISM; PATHOLOGY; RENAL INSUFFICIENCY, CHRONIC; CHRONIC KIDNEY FAILURE;

ANIMALS; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; ERYTHROCYTE MEMBRANE; FATTY ACIDS, OMEGA-3; HUMANS; LIPID METABOLISM; RENAL INSUFFICIENCY, CHRONIC;

EID: 84877249614     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/712949     Document Type: Review

References (78)

1. Foley R. N., Parfrey P. S., Sarnak M. J., Clinical epidemiology of cardiovascular disease in chronic renal disease. American Journal of Kidney Diseases 1998 32 5, supplement 3 S112 S119 2-s2.0-0031733696 (Pubitemid 28527268)
2. Go A. S., Chertow G. M., Fan D., McCulloch C. E., Hsu C. Y., Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. The New England Journal of Medicine 2004 351 13 1296 1305 2-s2.0-4644221457 10.1056/NEJMoa041031 (Pubitemid 39268908)
3. Stenvinkel P., Heimbürger O., Lindholm B., Kaysen G. A., Bergström J., Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrology Dialysis Transplantation 2000 15 7 953 960 2-s2.0-0342588054 (Pubitemid 30410364)
4. Sarnak M. J., Levey A. S., Schoolwerth A. C., Coresh J., Culleton B., Hamm L. L., McCullough P. A., Kasiske B. L., Kelepouris E., Klag M. J., Parfrey P., Pfeffer M., Raij L., Spinosa D. J., Wilson P. W., Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003 42 5 1050 1065 2-s2.0-0242441465 10.1161/01.HYP.0000102971. 85504.7c (Pubitemid 37413751)
5. Schiffrin E. L., Lipman M. L., Mann J. F. E., Chronic kidney disease: effects on the cardiovascular system. Circulation 2007 116 1 85 97 2-s2.0-34347350171 10.1161/CIRCULATIONAHA.106.678342 (Pubitemid 47016250)
6. Harper C. R., Jacobson T. A., Managing dyslipidemia in chronic kidney disease. Journal of the American College of Cardiology 2008 51 25 2375 2384 2-s2.0-44949180810 10.1016/j.jacc.2008.03.025 (Pubitemid 351815163)
7. Mizobuchi M., Towler D., Slatopolsky E., Vascular calcification: the killer of patients with chronic kidney disease. Journal of the American Society of Nephrology 2009 20 7 1453 1464 2-s2.0-67649678424 10.1681/ASN.2008070692
8. Marchioli R., Dietary supplementation with N-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. The Lancet 1999 354 9177 447 455 2-s2.0-0345109256 10.1016/S0140-6736(99)07072-5 (Pubitemid 29368922)
9. Dyerberg J., Bang H. O., Hjorne N., Fatty acid composition of the plasma lipids in Greenland Eskimos. American Journal of Clinical Nutrition 1975 28 9 958 966 2-s2.0-0016809013
10. Hu F. B., Bronner L., Willett W. C., Stampfer M. J., Rexrode K. M., Albert C. M., Hunter D., Manson J. E., Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. Journal of the American Medical Association 2002 287 14 1815 1821 2-s2.0-0037051975 (Pubitemid 34303626)
11. An W. S., Kim S. E., Kim K. H., Lee S., Park Y., Kim H. J., Vaziri N. D., Comparison of fatty acid contents of erythrocyte membrane in hemodialysis and peritoneal dialysis patients. Journal of Renal Nutrition 2009 19 4 267 274 2-s2.0-66949111736 10.1053/j.jrn.2009.01.027
12. Eslick G. D., Howe P. R. C., Smith C., Priest R., Bensoussan A., Benefits of fish oil supplementation in hyperlipidemia: a systematic review and meta-analysis. International Journal of Cardiology 2009 136 1 4 16 2-s2.0-67649882789 10.1016/j.ijcard.2008.03.092
13. Tomiyama H., Takazawa K., Osa S. I., Hirose K. I., Hirai A., Iketani T., Monden M., Sanoyama K., Yamashina A., Do eicosapentaenoic acid supplements attenuate age-related increases in arterial stiffness in patients with dyslipidemia?: a preliminary study. Hypertension Research 2005 28 8 651 655 2-s2.0-27744450343 10.1291/hypres.28.651 (Pubitemid 41601038)
14. Hall W. L., Sanders K. A., Sanders T. A. B., Chowienczyk P. J., A high-fat meal enriched with eicosapentaenoic acid reduces postprandial arterial stiffness measured by digital volume pulse analysis in healthy men. Journal of Nutrition 2008 138 2 287 291 2-s2.0-38949149696 (Pubitemid 351213641)
15. Kanai S., Uto K., Honda K., Hagiwara N., Oda H., Eicosapentaenoic acid reduces warfarin-induced arterial calcification in rats. Atherosclerosis 2011 215 1 43 51 2-s2.0-79952103048 10.1016/j.atherosclerosis.2010.12.001
16. Kang J. X., Leaf A., Evidence that free polyunsaturated fatty acids modify Na+ channels by directly binding to the channel proteins. Proceedings of the National Academy of Sciences of the United States of America 1996 93 8 3542 3546 2-s2.0-0029928093 10.1073/pnas.93.8.3542 (Pubitemid 26125657)
17. Leaf A., The electrophysiologic basis for the antiarrhythmic and anticonvulsant effects of n-3 polyunsaturated fatty acids: heart and brain. Lipids 2001 36, supplement S107 S110 2-s2.0-0035698468 (Pubitemid 34106218)
18. Shearer G. C., Pottala J. V., Spertus J. A., Harris W. S., Red blood cell fatty acid patterns and acute coronary syndrome. PLoS ONE 2009 4 5 2-s2.0-65549152876 10.1371/journal.pone.0005444 e5444
19. Hussein N., Ah-Sing E., Wilkinson P., Leach C., Griffin B. A., Millward D. J., Long-chain conversion of [13C]linoleic acid and α -linolenic acid in response to marked changes in their dietary intake in men. Journal of Lipid Research 2005 46 2 269 280 2-s2.0-13944270939 10.1194/jlr.M400225-JLR200 (Pubitemid 40271091)
20. Friedman A., Moe S., Review of the effects of omega-3 supplementation in dialysis patients. Clinical Journal of the American Society of Nephrology 2006 1 2 182 192 2-s2.0-33646806012 10.2215/CJN.00740805 (Pubitemid 43334212)
21. Grimsgaard S., Bønaa K. H., Hansen J. B., Myhre E. S. P., Effects of highly purified eicosapentaenoic acid and docosahexaenoic acid on hemodynamics in humans. American Journal of Clinical Nutrition 1998 68 1 52 59 2-s2.0-0031801260 (Pubitemid 28307654)
22. Harris W. S., Von Schacky C., The Omega-3 Index: a new risk factor for death from coronary heart disease? Preventive Medicine 2004 39 1 212 220 2-s2.0-2942724415 10.1016/j.ypmed.2004.02.030 (Pubitemid 38797975)
23. Harris W. S., Sands S. A., Windsor S. L., Omega-3 fatty acids in cardiac biopsies from heart transplantation patients: correlation with erythrocytes and response to supplementation. Circulation 2004 110 12 1645 1649 (Pubitemid 39297988)
24. Rangel-Huerta O. D., Aguilera C. M., Mesa M. D., Gil A., Omega-3 long-chain polyunsaturated fatty acids supplementation on inflammatory biomakers: a systematic review of randomised clinical trials. British Journal of Nutrition 2012 107 supplement 2 S159 S170
25. Ågren J. J., Väisänen S., Hänninen O., Muller A. D., Hornstra G., Hemostatic factors and platelet aggregation after a fish-enriched diet or fish oil or docosahexaenoic acid supplementation. Prostaglandins Leukotrienes and Essential Fatty Acids 1997 57 4-5 419 421 2-s2.0-0030811405 (Pubitemid 27504736)
26. Archer S. L., Green D., Chamberlain M., Dyer A. R., Liu K., Association of dietary fish and n-3 fatty acid intake with hemostatic factors in the coronary artery risk development in young adults (CARDIA)study. Arteriosclerosis, Thrombosis, and Vascular Biology 1998 18 7 1119 1123 2-s2.0-0031947046 (Pubitemid 28323596)
27. Kaysen G. A., The microinflammatory state in uremia: causes and potential consequences. Journal of the American Society of Nephrology 2001 12 7 1549 1557 2-s2.0-0034918979 (Pubitemid 32666340)
28. Muntner P., Hamm L. L., Kusek J. W., Chen J., Whelton P. K., He J., The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Annals of Internal Medicine 2004 140 1 9 17 2-s2.0-0347716452
29. Pischon T., Hankinson S. E., Hotamisligil G. S., Rifai N., Willett W. C., Rimm E. B., Habitual dietary intake of n-3 and n-6 fatty acids in relation to inflammatory markers among US men and women. Circulation 2003 108 2 155 160 2-s2.0-0038447923 10.1161/01.CIR.0000079224.46084.C2 (Pubitemid 36871296)
30. Perunicic-Pekovic G. B., Rasic Z. R., Pljesa S. I., Sobajic S. S., Djuricic I., Maletic R., Ristic-Medic D. K., Effect of n-3 fatty acids on nutritional status and inflammatory markers in haemodialysis patients. Nephrology 2007 12 4 331 336 2-s2.0-34447545528 10.1111/j.1440-1797.2007.00777.x (Pubitemid 47075407)
31. Hassan K. S., Hassan S. K., Hijazi E. G., Khazim K. O., Effects of omega-3 on lipid profile and inflammation markers in peritoneal dialysis patients. Renal Failure 2010 32 9 1031 1035 2-s2.0-77957252480 10.3109/0886022X.2010.510231
32. An W. S., Kim H. J., Cho K. H., Vaziri N. D., Omega-3 fatty acid supplementation attenuates oxidative stress, inflammation, and tubulointerstitial fibrosis in the remnant kidney. American Journal of Physiology 2009 297 4 F895 F903 2-s2.0-70349649783 10.1152/ajprenal.00217.2009
33. Serhan C. N., Chiang N., Van Dyke T. E., Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nature Reviews Immunology 2008 8 5 349 361 2-s2.0-42649089790 10.1038/nri2294 (Pubitemid 351595216)
34. James M., Proudman S., Cleland L., Fish oil and rheumatoid arthritis: past, present and future. Proceedings of the Nutrition Society 2010 69 3 316 323 2-s2.0-77957353557 10.1017/S0029665110001564
35. Deike E., Bowden R. G., Moreillon J. J., The effects of fish oil supplementation on markers of inflammation in chronic kidney disease patients. Journal of Renal Nutrition 2012 22 6 572 577
36. O'Keefe J. H. Jr., Abuissa H., Sastre A., Steinhaus D. M., Harris W. S., Effects of omega-3 fatty acids on resting heart rate, heart rate recovery after exercise, and heart rate variability in men with healed myocardial infarctions and depressed ejection fractions. American Journal of Cardiology 2006 97 8 1127 1130 2-s2.0-33645738072 10.1016/j.amjcard.2005.11.025
37. Mozaffarian D., Prineas R. J., Stein P. K., Siscovick D. S., Dietary fish and n-3 fatty acid intake and cardiac electrocardiographic parameters in humans. Journal of the American College of Cardiology 2006 48 3 478 484 2-s2.0-33746208045 10.1016/j.jacc.2006.03.048 (Pubitemid 44093963)
38. Kang J. X., Reduction of heart rate by omega-3 fatty acids and the potential underlying mechanisms. Frontiers in Cardiac Electrophysiology 2012 3, article 416
39. Kris-Etherton P. M., Harris W. S., Appel L. J., Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002 106 21 2747 2757 2-s2.0-0037137299 10.1161/01.CIR.0000038493.65177.94 (Pubitemid 35364932)
40. Zhao Y. T., Chen Q., Sun Y. X., Li X. B., Zhang P., Xu Y., Guo J. H., Prevention of sudden cardiac death with omega-3 fatty acids in patients with coronary heart disease: a meta-analysis of randomized controlled trials. Annals of Medicine 2009 41 4 301 310 2-s2.0-67349092346 10.1080/07853890802698834
41. Katan M. B., Zock P. L., Mensink R. P., Dietary oils, serum lipoproteins, and coronary heart disease. American Journal of Clinical Nutrition 1995 61 6, supplement S1368 S1373 2-s2.0-0029071159
42. Grundy S. M., Hegsted D. M., Astrup A., Hill J. O., Saris W. H. M., Taubes G., Dietary fat: at the heart of the matter. Science 2001 293 5531 801 804 2-s2.0-0035800726
43. An W. S., Lee S. M., Son Y. K., Effect of omega-3 fatty acids on the modification of erythrocyte membrane fatty acid content including oleic acid in peritoneal dialysis patients. Prostaglandins Leukotrienes and Essential Fatty Acids 2012 86 1-2 29 34
44. An W. S., Lee S. M., Son Y. K., Omega-3 fatty acid supplementation increases 1, 25-dihydroxyvitamin D and fetuin-A levels in dialysis patients. Nutrition Research 2012 32 7 495 502
45. Riediger N. D., Othman R. A., Suh M., Moghadasian M. H., A systemic review of the roles of n-3 fatty acids in health and disease. Journal of the American Dietetic Association 2009 109 4 668 679 2-s2.0-62749169989 10.1016/j.jada.2008.12.022
46. Egan B. M., Lu G., Greene E. L., Vascular effects of non-esterified fatty acids: implications for the cardiovascular risk factor cluster. Prostaglandins Leukotrienes and Essential Fatty Acids 1999 60 5-6 411 420 2-s2.0-0032772463 10.1016/S0952-3278(99)80022-2 (Pubitemid 29401802)
47. Lu G., Greene E. L., Nagai T., Egan B. M., Reactive oxygen species are critical in the oleic acid-mediated mitogenic signaling pathway in vascular smooth muscle cells. Hypertension 1998 32 6 1003 1010 2-s2.0-0032407020 (Pubitemid 29001427)
48. Block R. C., Harris W. S., Reid K. J., Spertus J. A., Omega-6 and trans fatty acids in blood cell membranes: a risk factor for acute coronary syndromes? American Heart Journal 2008 156 6 1117 1123 2-s2.0-56349113182 10.1016/j.ahj.2008.07.014
49. Paganelli F., Maixent J. M., Duran M. J., Parhizgar R., Pieroni G., Sennoune S., Altered erythrocyte n-3 fatty acids in Mediterranean patients with coronary artery disease. International Journal of Cardiology 2001 78 1 27 32 2-s2.0-0035085483 10.1016/S0167-5273(00)00442-3 (Pubitemid 32232134)
50. Son Y. K., Lee S. M., Kim S. E., Association between vascular calcification scores on plain radiographs and fatty acid contents of erythrocyte membrane in hemodialysis patients. Journal of Renal Nutrition 2012 22 1 58 66
51. Ando M., Sanaka T., Nihei H., Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of LDL in dialysis patients. Journal of the American Society of Nephrology 1999 10 10 2177 2184 2-s2.0-0032861520 (Pubitemid 29453496)
52. Sampath H., Ntambi J. M., Polyunsaturated fatty acid regulation of genes of lipid metabolism. Annual Review of Nutrition 2005 25 317 340 2-s2.0-23944435868 10.1146/annurev.nutr.25.051804.101917 (Pubitemid 41209005)
53. Harris W. S., Bulchandani D., Why do omega-3 fatty acids lower serum triglycerides? Current Opinion in Lipidology 2006 17 4 387 393 2-s2.0-33746040070 10.1097/01.mol.0000236363.63840.16 (Pubitemid 44079475)
54. Kearney P. M., Blackwell L., Collins R., Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. The Lancet 2008 371 9607 117 125 2-s2.0-38049033935 10.1016/S0140-6736(08)60104-X
55. Weiner D. E., Sarnak M. J., Managing dyslipidemia in chronic kidney disease. Journal of General Internal Medicine 2004 19 10 1045 1052 2-s2.0-7244238435 10.1111/j.1525-1497.2004.40049.x (Pubitemid 39431142)
56. Holick M. F., Medical progress: vitamin D deficiency. The New England Journal of Medicine 2007 357 3 266 281 2-s2.0-34447514029 10.1056/NEJMra070553 (Pubitemid 47080391)
57. Garland C. F., Gorham E. D., Mohr S. B., Garland F. C., Vitamin D for cancer prevention: global perspective. Annals of Epidemiology 2009 19 7 468 483 2-s2.0-66449083031 10.1016/j.annepidem.2009.03.021
58. Mezawa H., Sugiura T., Watanabe M., Norizoe C., Takahashi D., Shimojima A., Tamez S., Tsutsumi Y., Yanaga K., Urashima M., Serum vitamin D levels and survival of patients with colorectal cancer: post-hoc analysis of a prospective cohort study. BMC Cancer 2010 10, article 347 2-s2.0-77954040131 10.1186/1471-2407-10-347
59. Danescu L. G., Levy S., Levy J., Vitamin D and diabetes mellitus. Endocrine 2009 35 1 11 17 2-s2.0-63449138217 10.1007/s12020-008-9115-5
60. Kayaniyil S., Vieth R., Retnakaran R., Knight J. A., Qi Y., Gerstein H. C., Perkins B. A., Harris S. B., Zinman B., Hanley A. J., Association of vitamin D with insulin resistance and β -cell dysfunction in subjects at risk for type 2 diabetes. Diabetes Care 2010 33 6 1379 1381 2-s2.0-77955468245 10.2337/dc09-2321
61. Theuer J., Shagdarsuren E., Muller D. N., Kaergel E., Honeck H., Park J. K., Fiebeler A., Dechend R., Haller H., Luft F. C., Schunck W. H., Inducible NOS inhibition, eicosapentaenoic acid supplementation, and angiotensin II-induced renal damage. Kidney International 2005 67 1 248 258 2-s2.0-19944420123 10.1111/j.1523-1755.2005.00075.x (Pubitemid 40019246)
62. Rigby W. F. C., Denome S., Fanger M. W., Regulation of lymphokine production and human T lymphocyte activation by 1,25-dihydroxyvitamin D3. Specific inhibition at the level of messenger RNA. The Journal of Clinical Investigation 1987 79 6 1659 1664 2-s2.0-0023267970 (Pubitemid 17117271)
63. Li Y. C., Qiao G., Uskokovic M., Xiang W., Zheng W., Kong J., Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure. Journal of Steroid Biochemistry and Molecular Biology 2004 89-90 387 392 2-s2.0-3042594296 10.1016/j.jsbmb.2004.03.004 (Pubitemid 38844316)
64. Li Y. C., Kong J., Wei M., Chen Z. F., Liu S. Q., Cao L. P., 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system. The Journal of Clinical Investigation 2002 110 2 229 238 2-s2.0-0036073755 10.1172/JCI200215219 (Pubitemid 34787360)
65. Wang T. J., Pencina M. J., Booth S. L., Jacques P. F., Ingelsson E., Lanier K., Benjamin E. J., D'Agostino R. B., Wolf M., Vasan R. S., Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008 117 4 503 511 2-s2.0-41049096380 10.1161/CIRCULATIONAHA.107.706127
66. Melamed M. L., Michos E. D., Post W., Astor B., 25-hydroxyvitamin D levels and the risk of mortality in the general population. Archives of Internal Medicine 2008 168 15 1629 1637 2-s2.0-49449104636 10.1001/archinte.168.15.1629
67. Melamed M. L., Astor B., Michos E. D., Hostetter T. H., Powe N. R., Muntner P., 25-Hydroxyvitamin D levels, race, and the progression of kidney disease. Journal of the American Society of Nephrology 2009 20 12 2631 2639 2-s2.0-72049115797 10.1681/ASN.2009030283
68. Santoro D., Gitto L., Ferraro A., Satta E., Savica V., Bellinghieri G., Vitamin D status and mortality risk in patients with chronic kidney disease. Renal Failure 2011 33 2 184 191 2-s2.0-79951970134 10.3109/0886022X.2011.553303
69. Zehnder D., Bland R., Walker E. A., Bradwell A. R., Howie A. J., Hewison M., Stewart P. M., Expression of 25-hydroxyvitamin D3-1 α -hydroxylase in the human kidney. Journal of the American Society of Nephrology 1999 10 12 2465 2473 2-s2.0-0032727633
70. Artaza J. N., Mehrotra R., Norris K. C., Vitamin D and the cardiovascular system. Clinical Journal of the American Society of Nephrology 2009 4 9 1515 1522 2-s2.0-70350398576 10.2215/CJN.02260409
71. Shobeiri N P. J., Adams M. A., Holden R. M., Cardiovascular disease in an adenine-induced model of chronic kidney disease: the temporal link between vascular calcification and haemodynamic consequences. Journal of Hypertension 2013 31 1 160 168
72. Nishizawa H., Hamazaki K., Hamazaki T., Fujioka S., Sawazaki S., The relationship between tissue RBC n-3 fatty acids and pulse wave velocity. In Vivo 2006 20 2 307 310 2-s2.0-33645781588
73. Szweras M., Liu D., Partridge E. A., Pawling J., Sukhu B., Clokie C., Jahnen-Dechent W., Tenenbaum H. C., Swallow C. J., Grynpas M. D., Dennis J. W., α 2-HS glycoprotein/fetuin, a transforming growth factor β /bone morphogenetic protein antagonist, regulates postnatal bone growth and remodeling. The Journal of Biological Chemistry 2002 277 22 19991 19997 2-s2.0-0037205407 10.1074/jbc.M112234200 (Pubitemid 34967522)
74. Burr M. L., Fehily A. M., Gilbert J. F., Rogers S., Holliday R. M., Sweetnam P. M., Elwood P. C., Deadman N. M., Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). The Lancet 1989 2 8666 757 761 2-s2.0-0024363690 (Pubitemid 19234807)
75. Kromhout D., Giltay E. J., Geleijnse J. M., N-3 fatty acids and cardiovascular events after myocardial infarction. The New England Journal of Medicine 2010 363 21 2015 2026 2-s2.0-78549233384 10.1056/NEJMoa1003603
76. Rizos E. C., Ntzani E. E., Bika E., Kostapanos M. S., Elisaf M. S., Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. Journal of the American Medical Association 2012 308 10 1024 1033
77. Christensen J. H., Aarøe J., Knudsen N., Dideriksen K., Kornerup H. J., Dyerberg J., Schmidt E. B., Heart rate variability and n-3 fatty acids in patients with chronic renal failure-a pilot study. Clinical Nephrology 1998 49 2 102 106 2-s2.0-0031929273 (Pubitemid 28073502)
78. Mori T. A., Burke V., Puddey I. B., Irish A. B., Cowpland C. A., Beilin L. J., Dogra G. K., Watts G. F., The effects of ω 3 fatty acids and coenzyme Q10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial. Journal of Hypertension 2009 27 9 1863 1872 2-s2.0-73249137129 10.1097/HJH.0b013e32832e1bd9